Keros Therapeutics (KROS) Free Cash Flow Growth (3y) (2022 - 2025)
Keros Therapeutics (KROS) Free Cash Flow Growth (3y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 21.16% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 45.09% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 80.69% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -23.92% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 8.92% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -4.45% |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.27% |
| Sep 30, 2025 | 29.85% |
| Jun 30, 2025 | -9.33% |
| Mar 31, 2025 | 376.34% |
| Dec 31, 2024 | -32.90% |
| Sep 30, 2024 | -26.37% |
| Jun 30, 2024 | -32.81% |
| Mar 31, 2024 | -61.09% |
| Dec 31, 2023 | -48.18% |
| Sep 30, 2023 | -48.00% |
| Jun 30, 2023 | -47.87% |
| Mar 31, 2023 | -60.43% |
| Dec 31, 2022 | -57.39% |
| Sep 30, 2022 | -98.91% |
| Jun 30, 2022 | -64.63% |
| Mar 31, 2022 | 15.54% |